ERBB2 and breast neoplasm: Clinical treatment decisions are driven by the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) and the classification of breast tumors according to their receptor status into HER2-positive, ER-positive/HER2-negative, and triple-negative clinical subtypes.